If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences

The rise of biosimilars, the name given to generic versions of biologic drugs such as monoclonal antibodies and granulocyte colony-stimulating growth factors, hasn't quite lived up to the hype in recent years.

The U.S. Food and Drug Administration (FDA) has approved 24 biosimilars, but many haven't made it to the market yet.